Breaking News

Samsung Biologics Adopts Solentim Solutions in R&D Center

Solentim’s instruments will be used in conjunction with Samsung Biologics’ proprietary cell line platform.

By: Contract Pharma

Contract Pharma Staff

Solentim’s VIPS single cell seeding platform and Cell Metric CLD have been adopted into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development.   Samsung’s new R&D facility in San Francisco will offer rapid, high-quality development services, including cell line development, to its global customers. Solentim’s VIPS ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters